Supportive Care in Cancer

, Volume 15, Issue 11, pp 1319–1323 | Cite as

Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better

  • José F. Duarte Souza
  • Paula P. Lajolo
  • Hélio Pinczowski
  • Auro del GiglioEmail author
Short Communiation



Adjunct nonopioid analgesics may improve pain control in patients with cancer needing morphine or its derivates. Dypirone is a cheap nonopioid analgesic widely used in many countries.


The objective of the study was to evaluate, whenever morphine was started, if associating dipyrone with it would improve pain control and if this effect was time dependent.

Materials and methods

This is a double-blind placebo-controlled randomized crossover study. Thirty-four ambulatory cancer patients experiencing cancer-related pain for which oral morphine was to be started at the dose of 10 mg orally (PO) every 4 h were randomized to take either dipyrone 500 mg PO every 6 h or placebo. After 48 h, patients would be switched from dipyrone to placebo and vice versa. Pain was the primary outcome and was measured using a visual analogue scale before starting medications, at 48 and 96 h.


We randomized 16 patients to start with placebo (group 1) and 18 with dipyrone (group 2). Pain scores for groups 1 and 2 were at baseline: 7.31 ± 0.29 vs 6.88 ± 0.28 (p = 0.3), at 48 h: 7.06 ± 0.32 vs 5.5 ± 0.31 (p = 0.001), and at 96 h: 3.18 ± 0.39 vs 1.94 ± 0.37 (p = 0.03). Both groups had significant improvements in pain scores after introducing dipyrone (p < 0.001, for both). Main toxicities were nausea, vomiting, epigastric pain, and myalgias. Twenty-eight patients chose dipyrone, four placebo, and two were indifferent.


We conclude that dipyrone adds significantly to the analgesic effect of morphine and, when given at the time of starting morphine, results in better pain scores even after dipyrone is discontinued.


Dipyrone Double-blind method Drug administration schedule Morphine Neoplasms Pain Pain measurement 


  1. 1.
    Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA et al (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427, Oct 5PubMedCrossRefGoogle Scholar
  2. 2.
    Fallon M, Hanks G, Cherny N (2006) Principles of control of cancer pain. BMJ 332(7548):1022–1024, Apr 29PubMedCrossRefGoogle Scholar
  3. 3.
    Volz M, Kellner HM (1980) Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 10(Suppl 2):299S–308S, OctPubMedGoogle Scholar
  4. 4.
    Edwards JE, Meseguer F, Faura CC, Moore RA, McQuay HJ (2001) Single-dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 3:CD003227PubMedGoogle Scholar
  5. 5.
    Shinar E, Hershko C (1983) Causes of agranulocytosis in a hospital population: identification of dipyrone as an important causative agent. Isr J Med Sci 19(3):225–229 MarPubMedGoogle Scholar
  6. 6.
    Heit WF (1983) Hematologic effects of antipyretic analgesics. Drug-induced agranulocytosis. Am J Med 75(5A):65–69, Nov 14PubMedCrossRefGoogle Scholar
  7. 7.
    Hamerschlak N, Cavalcanti AB (2005) Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J 123(5):247–249, Sep 1PubMedCrossRefGoogle Scholar
  8. 8.
    Backstrom M, Hagg S, Mjorndal T, Dahlqvist R (2002) Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf 11(3):239–245, AprPubMedCrossRefGoogle Scholar
  9. 9.
    Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 60(11):821–829, JanPubMedCrossRefGoogle Scholar
  10. 10.
    Laporte JR, Carne X, Vidal X, Moreno V, Juan J (1991) Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 337(8733):85–89, Jan 12PubMedCrossRefGoogle Scholar
  11. 11.
    Stockler M, Vardy J, Pillai A, Warr D ( 2004) Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 22(16):3389–3394, Aug 15PubMedCrossRefGoogle Scholar
  12. 12.
    Kampe S, Warm M, Landwehr S, Dagtekin O, Haussmann S, Paul M et al (2006) Clinical equivalence of IV paracetamol compared to IV dipyrone for postoperative analgesia after surgery for breast cancer. Curr Med Res Opin 22(10):1949–1954, OctPubMedCrossRefGoogle Scholar
  13. 13.
    Rodriguez M, Barutell C, Rull M, Galvez R, Pallares J, Vidal F et al (1994) Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. Eur J Cancer 30A(5):584–587PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • José F. Duarte Souza
    • 1
  • Paula P. Lajolo
    • 2
    • 3
  • Hélio Pinczowski
    • 2
  • Auro del Giglio
    • 2
    • 3
    Email author
  1. 1.Universidade Federal de São PauloSão PauloBrazil
  2. 2.Department of Hematology and OncologyABC Foundation School of MedicineSão PauloBrazil
  3. 3.Oncology DepartmentAlbert Einstein HospitalSão PauloBrazil

Personalised recommendations